January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
12 citations
,
November 2006 in “Journal of thoracic oncology” A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
July 2021 in “Journal of dermatology & dermatologic surgery” IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
October 2024 in “Asian Journal of Pharmaceutical and Clinical Research” Topical methotrexate is more effective and as safe as betamethasone for treating alopecia areata.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
December 2025 in “Педиатрическая фармакология” Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
1 citations
,
November 2025 in “Neuro-Oncology” Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
8 citations
,
September 2013 in “Molecular carcinogenesis” Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
24 citations
,
January 2017 in “International Journal of Trichology”
The treatment was ineffective in humans.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
6 citations
,
December 2018 in “Ophthalmic Plastic and Reconstructive Surgery” Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.
February 2025 in “Revista Eletrônica Acervo Saúde” Triamcinolone hexacetonide is effective but has side effects, while PRP and minoxidil are safer alternatives for treating alopecia areata.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
March 2022 in “International Journal of Trichology” Erlotinib can cause unusual hair growth, like long eyelashes and facial hair.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.